10.6084/m9.figshare.9327251.v1
Morganna Freeman
Morganna
Freeman
Keith A. Betts
Keith A.
Betts
Shan Jiang
Shan
Jiang
Ella X. Du
Ella X.
Du
Komal Gupte-Singh
Komal
Gupte-Singh
Yichen Lu
Yichen
Lu
Sumati Rao
Sumati
Rao
Alexander N. Shoushtari
Alexander N.
Shoushtari
Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data
Adis Journals
2019
Adjuvant treatment
Costs per recurrence-free life-month
Costs per recurrence-free survivor
Ipilimumab
Melanoma
Nivolumab
Number needed to treat
Observation
2019-08-19 08:51:50
Figure
https://adisjournals.figshare.com/articles/figure/Indirect_Treatment_Comparison_of_Nivolumab_Versus_Observation_or_Ipilimumab_as_Adjuvant_Therapy_in_Resected_Melanoma_Using_Pooled_Clinical_Trial_Data/9327251
<p><strong>Provide enhanced digital features for this article</strong><br></p><p>
If you are an author of this publication and would like to provide additional
enhanced digital features for your article then please contact <u>adisrapidplus@springer.com</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to ensure
the content is of the highest scientific standard and all features are marked
as ‘peer reviewed’ to ensure readers are aware that the content has been
reviewed to the same level as the articles they are being presented alongside.
Moreover, all sponsorship and disclosure information is included to provide
complete transparency and adherence to good publication practices. This ensures
that however the content is reached the reader has a full understanding of its
origin. No fees are charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are not limited to:<br>
• Slide decks<br>
• Videos and animations<br>
• Audio abstracts<br>
• Audio slides</p>
<p> </p>